Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age

Vaccine

Volumn 30, Issue 17, 2012, Pages 2710-2714

  Van Der Meeren, Olivier ^a   Kuriyakose, Sherine ^b   Kolhe, Devayani ^b   Hardt, Karin ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

Booster; Combination vaccines; Immunogenicity; Polio; Vaccine

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; DIPHTHERIA; FEMALE; GEOMETRY; GROUPS BY AGE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MALE; NORMAL HUMAN; POLIOMYELITIS; PRIORITY JOURNAL; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS VACCINES; HEPATITIS B; HUMANS; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; TETANUS; TIME FACTORS; VACCINES, COMBINED;

EID: 84858708002     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.024     Document Type: Article

References (16)

1. National Childhood Vaccination Schedules. Available from: [accessed 06 July 2011]. http://www.euvac.net/graphics/euvac/vaccination/vaccination.html.
2. Allgemeiner Impfplan [Internet]. netdoktor.at. Available from: [accessed January 28 2012]. http://www.netdoktor.at/health_center/impfen/impfplan.shtml.
3. Kalies H., Grote V., Verstraeten T., Hessel L., Schmitt H-J., von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006, 25:507-512.
4. Marshall G.S., Happe L.E., Lunacsek O.E., Szymanski M.D., Woods C.R., Zahn M., et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007, 26:496-500.
5. Zepp F., Schmitt H-J., Cleerbout J., Verstraeten T., Schuerman L., Jacquet J-M. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009, 8:663-678.
6. Avdicová M., Prikazský V., Hudecková H., Schuerman L., Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002, 161:581-587.
7. Gabutti G., Zepp F., Schuerman L., Dentico P., Bamfi F., Soncini R., et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 2004, 36:585-592.
8. Kilpi T.M., Silfverdal S.A., Nilsson L., Syrjänen R., Belloni C., Desole M., et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccines 2009, 5:18-25.
9. World Health Organisation Standard procedure for determining immunity to poliovirus using the microneutralisation test 1993, WHO/EPI/GEN 93.9.
10. Zepp F., Schmitt H.J., Kaufhold A., Schuind A., Knuf M., Habermehl P., et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 1997, 156(1):18-24.
11. Schmitt H.J., Knuf M., Ortiz E., Sänger R., Uwamwezi M.C., Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000, 137:304-312.
12. Heininger U., Sänger R., Jacquet J-M., Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007, 25:1055-1063.
13. Carlsson R.M., Claesson B.A., Selstam U., Fagerlund E., Granström M., Blondeau C., et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998, 17:1026-1033.
14. Taranger J., Trollfors B., Knutsson N., Sundh V., Lagergård T., Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 1999, 18:884-891.
15. Hallander H.O., Lepp T., Ljungman M., Netterlid E., Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 2010, 118:878-887.
16. Carlsson R-M., Trollfors B. Control of pertussis-lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009, 27:5709-5718.